Literature DB >> 3711117

Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells.

M M Cornwell, M M Gottesman, I H Pastan.   

Abstract

Human KB carcinoma cells resistant to high levels of colchicine, vinblastine, vincristine, adriamycin, and actinomycin D exhibit reduced accumulation of these structurally unrelated chemotherapeutic agents (Akiyama, S.-I., Fojo, A., Hanover, J. A., Pastan, I., and Gottesman, M. M. (1985) Somatic Cell Mol. Genet. 11, 117-126; Fojo, A., Akiyama, S.-I., Gottesman, M. M., and Pastan, I. (1985) Cancer Res. 45, 3002-3007). To examine the mechanism of reduced drug accumulation in these cells, we measured [3H]vinblastine ([3H]VBL) binding to membrane vesicles made from drug-sensitive (KB-3-1), drug-resistant (KB-C4), and revertant (KB-R1) cells. Membrane vesicles from KB-C4 cells bound up to 8-fold more [3H]VBL than vesicles from the parental KB-3-1 or revertant KB-R1 cell lines. No difference in binding of [3H]dexamethasone, to which the cells are equally sensitive, was observed. The difference in [3H]VBL binding by vesicles from resistant and sensitive cells was eliminated by the addition of 10 micrograms/ml verapamil, which is known to reverse the multidrug-resistance phenotype. Drug binding by KB-C4 vesicles was osmotically insensitive, temperature-dependent, and trypsin-sensitive. Binding of [3H]VBL by KB-C4 vesicles was inhibited by vinblastine, vincristine, and daunomycin (in decreasing order). Dexamethasone at 100 microM, colchicine at 100 microM, and actinomycin D at 100 microM did not significantly inhibit [3H]VBL accumulation. No significant differences in tubulin content were detected among vesicles from sensitive and resistant cells. These data demonstrate that membrane vesicles from multiply drug-resistant cells bind increased amounts of vinblastine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3711117

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.

Authors:  W J Baker; V J Wiebe; S K Koester; V D Emshoff; J U Maenpaa; G T Wurz; M W DeGregorio
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 3.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps.

Authors:  P Gros; R Dhir; J Croop; F Talbot
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

5.  Expression of a multidrug-resistance gene in human tumors and tissues.

Authors:  A T Fojo; K Ueda; D J Slamon; D G Poplack; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

6.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Molecular mechanisms of drug resistance.

Authors:  J D Hayes; C R Wolf
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

Review 8.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Reversible penetration of alpha-glutathione S-transferase into biological membranes revealed by photosensitized labelling in situ.

Authors:  N Merezhinskaya; G A Kuijpers; Y Raviv
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

10.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

Authors:  Chun-ling Dai; Amit K Tiwari; Chung-Pu Wu; Xiao-Dong Su; Si-Rong Wang; Dong-geng Liu; Charles R Ashby; Yan Huang; Robert W Robey; Yong-ju Liang; Li-ming Chen; Cheng-Jun Shi; Suresh V Ambudkar; Zhe-Sheng Chen; Li-wu Fu
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.